中国急性冠脉综合征患者高强度他汀治疗的安全性研究进展

Research progress on safety of high-intensity statin therapy in Chinese patients with acute coronary syndrome

摘要:

他汀类药物是经典的羟甲基戊二酸单酰辅酶A还原酶抑制剂,能明显降低动脉粥样硬化性心血管疾病事件的发生率。最近,部分指南和共识均推荐急性冠脉综合征(ACS)患者应早期启动高强度他汀类药物治疗。但中国人群他汀副作用的发生率显著高于白种人。因此,应高度关注中国人群高强度他汀类药物治疗的不良反应。本文对中国ACS患者使用高强度他汀类药物治疗的安全性进行了综述,为临床用药提供参考。

Abstract:

Statins, inhibitors of 3-hydroxy-3-methylglutaryl coenzyme reductase, can significantly reduce the incidence of atherosclerotic cardiovascular disease (ASCVD) events. Recently, some guidelines and consensus have suggested that the patients with acute coronary syndromes (ACS) should start high-intensity statin therapy early after admission. But, Chinese patients tend to have higher incidence of side effects in statins treatment than Caucasians. Therefore, particular attention should be paid to the adverse reactions in Chinese population after high-intensity statin treatment. In this article, we reviewed the safety of high-intensity statin therapy in ACS patients in China, and provides a reference for clinical practice.